Valadez-Rodríguez JA, Herrera-Rodríguez SE, García-Márquez E

Language: Spanish
References: 56
Page: 210-218
PDF size: 346.73 Kb.

Text Extraction

No abstract.

REFERENCES

1. Andrews N. (2000). Iron homeostasis: insights from genetics and animal models. Nature reviews Genetics, 1, 208-217.

2. Anselmo, A. C., & Mitragotri, S. (2015). A Review of Clinical Translation of Inorganic Nanoparticles. Th e AAPS Journal.

3. Antoja , F., & Casamajó , M. T. (1985). Metabolismo del hierro plasmatico y sus mecanismos de transporte. Quimica Clínica, 4(3), 165-169.

4. Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. Bioengineering & Translational Medicine.

5. Arribas, J., & Vallina , E. (2005). Hematología Clínica Temas de Patología Médica Oviedo. 55-58. Textos universitarios ediuno.

6. Behrens, I., Vila Pena, A. I., Alonso, M. J., & Kissel, T. (2002). Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: Th e eff ect of mucus on particle adsorption and transport. Pharmaceutical Research.

7. Bernard, J., Levy, J. P., & Varet , B. (1982). Manual de hematología (3ra edición ed.). Barcelona: Toray-Masson.

8. Bobo, D., Robinson, K. J., Islam, J., Th urecht, K. J., & Corrie, S. R. (2016). Nanoparticle-Based Medicines: A Review of FDAApproved Materials and Clinical Trials to Date. Pharmaceutical Research.

9. Braithwaite, M. C., Tyagi, C., Tomar, L. K., Kumar, P., Choonara, Y. E., & Pillay, V. (2014). Nutraceutical-based therapeutics and formulation strategies augmenting their effi ciency to complement modern medicine: An overview. Journal of Functional Foods.

10. Chaundry, Q., Scotter, M., Blackburn, J., Ross, B., Boxall, A., Castle, L., Aitken, R., & Watkins, R. (2008). Applications and implications of nanotechnologies for the food sector. Food additives and contaminants, 25:3, 241-258.

11. Chen , H., Weiss, J., & Shahidi, F. (2006). Nanotechnology in nutraceuticals and functional foods. Food Technol, 60(3), 30-36.

12. CONRAD, M. E., & CROSBY, W. H. (1963). INTESTINAL MUCOSAL MECHANISMS CONTROLLING IRON ABSORPTION. Blood.

13. Conrad , M., & Umbreit , J. (2000). Iron absorption and transportan update. Am J Hematol, 64, 287-298.

14. De Benoist, B., McLean, E., Egli, I., & Cogswell, M. (2008). Worldwide prevalence of anemia 1993-2005: WHO global database on anemia.

15. Durán, E., Villalobos , C., Churio , O., Pizarro, F., & Valenzuela , C. (2017). Encapsulación de hierro: Otra estrategia para la prevención o tratamiento de la anemia por defi ciencia de hierro. Rev Chil Nutr, 4(3), 234-243.

16. Emerit, J., Beaumont, C., & Trivin, F. (2001). Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother, 55, 333-339.

17. Flanagan, P. R., McLellan, J. S., Haist, J., Cherian, G., Chamberlain, M. J., & Valberg, L. S. (1978). Increased dietary cadmium absorption in mice and human subjects with iron defi ciency. Gastroenterology.

18. Gómez, M. G., Campos, G. A., García, J. A., Ramírez G. (2005). Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas. Nefrología, 25:1, 9-19.

19. Goycoolea, F. M., Remuñán-López, C., & Alonso, M. (s.f.). Nanopartículas a base de polisacáridos: quitosano.

20. Hallberg, L., Brune, M., Erlandsson, M., Sandberg, A. S., & Rossander-Hulten, L. (1991). Calcium: Eff ect of diff erent amounts of nonheme- and heme-iron absorption in humans. American Journal of Clinical Nutrition.

21. Hallberg, L., Brune, M., & Rossander, L. (1989). Iron absorption in man: Ascorbic acid and dose-dependent inhibition by phytate. American Journal of Clinical Nutrition.

22. Hashem, F., Nasr, M., & Ahmed, Y. (2018). Preparation and evaluation of iron oxide nanoparticles for treatment of iron defi ciency anemia. International Journal of Pharmacy and Pharmaceutical Sciences, 10(1).

23. Heitbrink, W. A., Lo, L. M., & Dunn, K. H. (2015). Exposure controls for nanomaterials at three manufacturing sites. Journal of Occupational and Environmental Hygiene.

24. Hurrell, R. (2002a). How to Ensure Adequate Iron Absorption from Iron-fortifi ed Food. Nutrition Reviews.

25. Hurrell, R. F. (2002b). Fortifi cation: Overcoming Technical and Practical Barriers. Th e Journal of Nutrition.

26. Janes, K. A., Calvo, P., & Alonso, M. J. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Advanced Drug Delivery Reviews.

27. Kean, T., & Th anou, M. (2010). Biodegradation, biodistribution and toxicity of chitosan. Advanced Drug Delivery Reviews.

28. Kim, B. G., & Kang , I. J. (2006). Chitosan nanoparticles for the eff ective vaccine. Technical Proceedings, 2, 388-391.

29. Kuvibidila, S. R., Velez, M., Gardner, R., Penugonda, K., Chandra, L. C., & Yu, L. (2012). Iron defi ciency reduces serum and in vitro secretion of interleukin-4 in mice independent of altered spleen cell proliferation. Nutrition Research.

30. Latunde-Dada, G. O., McKie, A. T., & Simpson, R. J. (2006). Animal models with enhanced erythropoiesis and iron absorption. Biochimica et Biophysica Acta, 414-423.

31. Latunde-Dada, G. O., Pereira, D. I. A., Tempest, B., Ilyas, H., Flynn, A. C., Aslam, M. F., … Powell, J. J. (2014). A nanoparticulate ferritin-core mimetic is well taken up by HuTu 80 duodenal cells and its absorption in mice is regulated by body iron. Th e Journal of Nutrition.

32. Martínez-Salgado, H., Casanueva, E., Rivera-Dommarco, J., Viteri, F. E., & Bourgues-Rodríguez, H. (2008). La defi ciencia de hierro y la anemia en niños mexicanos. Acciones para prevenirlas y corregirlas. Bol Med Hosp Infant Mex, 65, 86-99.

33. McClements, D. J. (2015). Enhancing nutraceutical bioavailability through food matrix design. Current Opinion in Food Science.

34. McClements , D. J., & Xiao , H. (2017). Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles. Science food, 6, 1-13.

35. Mihai , A. G. (2017). Nutrient delivery (Vol. 5). (A. G. Mihai , Ed.) Bucharest: Elsevier.

36. Mirciov, C. S. G., Wilkins, S. J., Dunn, L. A., Anderson, G. J., & Frazer, D. M. (2017). Characterization of putative erythroid regulators of hepcidin in mouse models of anemia. PLoS ONE.

37. Muzzarelli , R. A., & Peter, M. G. (1997). Chitin Handbook. Grottammare: Elsevier Science Ltd.

38. Nair, H. B., Sung, B., Yadav, V. R., Kannappan, R., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Delivery of antiinfl ammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochemical Pharmacology.

39. Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of ultrafi ne particles. Environmental Health Perspectives.

40. Pan, Y., Li, Y. J., Zhao, H. Y., Zheng, J. M., Xu, H., Wei, G., … Cui, F. De. (2002). Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. International Journal of Pharmaceutics.

41. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology.

42. Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov, 9(8), 615-627.

43. Pountney, D. J., Konijn, A. M., McKie, A. T., Peters, T. J., Raja, K. B., Salisbury, J. R., & Simpson, R. J. (1999). Iron proteins of duodenal enterocytes isolated from mice with genetically and experimentally altered iron metabolism. British Journal of Haematology.

44. Prasitsilp, M., Jenwithisuk, R., Kongsuwan, K., Damrongchai, N., & Watts, P. (2000). Cellular responses to chitosan in vitro: Th e importance of deacetylation. Journal of Materials Science: Materials in Medicine.

45. Ramírez-Barragán, C. A., Delgado-Fornué, E., & Andrade- Ortega, J. A. (2016). Determinación del grado de desacetilación de quitosana mediante titulación potenciométrica, FTIR y Raman. Journal CIM, 4(1), 769-776.

46. Reddy, N. R., Sathe, S. K., & Salunkhe, D. K. (1982). Phytates in legumes and cereals. Advances in Food Research.

47. Sakata, S., Enoki, Y., Kohzuki H., & Morimoto , T. (1993). Plasma Bioactive Erythropoietin in Mice with Dietary Iron Defi ciency Anaemia: Enhanced Reticulocytosis and Recombinant Erythropoietin Administration. Comparative Hematology International, 3, 173-183.

48. Shaw, J. G., & Friedman, J. F. (2011). Iron defi ciency anemia: Focus on infectious diseases in lesser developed countries. Anemia.

49. Shen, Y., Posavec, L., Bolisetty, S., Hilty, F. M., Nyström, G., Kohlbrecher, J., … Mezzenga, R. (2017). Amyloid fi bril systems reduce, stabilize and deliver bioavailable nanosized iron. Nature Nanotechnology.

50. Sherwood, R. A., Pippard, M. J., & Peters, T. J. (1998). Iron homeostasis and the assessment of iron status. Ann Clin Biochem, 35, 693-708.

51. Siegenberg, D., Baynes, R. D., Bothwell, T. H., Macfarlane, B. J., Lamparelli, R. D., Car, N. G., … Mayet, F. (1991). Ascorbic acid prevents the dose-dependent inhibitory eff ects of polyphenols and phytates on nonheme-iron absorption. American Journal of Clinical Nutrition.

52. Wang, S., Su, R., Nie, S., Sun, M., Zhang, J., Wu, D., & Moustaid- Moussa, N. (2014). Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. Journal of Nutritional Biochemistry.

53. Wick, M., Pinggera, W., & Lehmann, P. (1996). Iron metabolism diagnosis and therapy of anemias. Springer-Verlag Wien GmbH.

54. World Health Organization. (2001). Iron Defi ciency Anaemia: Assessment, Prevention and Control, A guide for program managers. Who Guideline.

55. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Th erapeutic applications and developments. Clinical Pharmacology and Th erapeutics.

56. Zimmermann, M. B., Chaouki, N., & Hurrell, R. F. (2005). Iron defi ciency due to consumption of a habitual diet low in bioavailable iron: A longitudinal cohort study in Moroccan children. American Journal of Clinical Nutrition.